Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
44 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Hemispherx Biopharma, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Hemispherx Biopharma, Inc. - Product Pipeline Review - 2014', provides an overview of the Hemispherx Biopharma, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Hemispherx Biopharma, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Hemispherx Biopharma, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Hemispherx Biopharma, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Hemispherx Biopharma, Inc.'s pipeline products Reasons to buy - Evaluate Hemispherx Biopharma, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Hemispherx Biopharma, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Hemispherx Biopharma, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Hemispherx Biopharma, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Hemispherx Biopharma, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Hemispherx Biopharma, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Hemispherx Biopharma, Inc. Snapshot 5 Hemispherx Biopharma, Inc. Overview 5 Key Information 5 Key Facts 5 Hemispherx Biopharma, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Hemispherx Biopharma, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Combination Treatment Modalities 11 Hemispherx Biopharma, Inc. - Pipeline Products Glance 12 Hemispherx Biopharma, Inc. - Late Stage Pipeline Products 12 Pre-Registration Products/Combination Treatment Modalities 12 Filing rejected/Withdrawn Products/Combination Treatment Modalities 13 Hemispherx Biopharma, Inc. - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Hemispherx Biopharma, Inc. - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Hemispherx Biopharma, Inc. - Unknown Stage Pipeline Products 17 Unknown Products/Combination Treatment Modalities 17 Hemispherx Biopharma, Inc. - Drug Profiles 18 interferon alfa-n3 (human leukocyte derived) 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 rintatolimod 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Alferon LDO 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 interferon alfa-n3 injection + interferon alfa-n3 low dose oral 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Oragen 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Hemispherx Biopharma, Inc. - Pipeline Analysis 26 Hemispherx Biopharma, Inc. - Pipeline Products by Target 26 Hemispherx Biopharma, Inc. - Pipeline Products by Route of Administration 27 Hemispherx Biopharma, Inc. - Pipeline Products by Molecule Type 28 Hemispherx Biopharma, Inc. - Pipeline Products by Mechanism of Action 29 Hemispherx Biopharma, Inc. - Recent Pipeline Updates 30 Hemispherx Biopharma, Inc. - Dormant Projects 38 Hemispherx Biopharma, Inc. - Company Statement 39 Hemispherx Biopharma, Inc. - Locations And Subsidiaries 41 Head Office 41 Other Locations & Subsidiaries 41 Hemispherx Biopharma, Inc. - Key Manufacturing Facilities 42 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 44 Disclaimer 44
List of Tables Hemispherx Biopharma, Inc., Key Information 5 Hemispherx Biopharma, Inc., Key Facts 5 Hemispherx Biopharma, Inc. - Pipeline by Indication, 2014 8 Hemispherx Biopharma, Inc. - Pipeline by Stage of Development, 2014 9 Hemispherx Biopharma, Inc. - Monotherapy Products in Pipeline, 2014 10 Hemispherx Biopharma, Inc. - Combination Treatment Modalities in Pipeline, 2014 11 Hemispherx Biopharma, Inc. - Pre-Registration, 2014 12 Hemispherx Biopharma, Inc. - Filing rejected/Withdrawn, 2014 13 Hemispherx Biopharma, Inc. - Phase II, 2014 14 Hemispherx Biopharma, Inc. - Phase I, 2014 15 Hemispherx Biopharma, Inc. - Preclinical, 2014 16 Hemispherx Biopharma, Inc. - Unknown, 2014 17 Hemispherx Biopharma, Inc. - Pipeline by Target, 2014 26 Hemispherx Biopharma, Inc. - Pipeline by Route of Administration, 2014 27 Hemispherx Biopharma, Inc. - Pipeline by Molecule Type, 2014 28 Hemispherx Biopharma, Inc. - Pipeline Products by Mechanism of Action, 2014 29 Hemispherx Biopharma, Inc. - Recent Pipeline Updates, 2014 30 Hemispherx Biopharma, Inc. - Dormant Developmental Projects,2014 38 Hemispherx Biopharma, Inc., Subsidiaries 41 Hemispherx Biopharma, Inc., Key Manufacturing Facilities 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.